Skip to main content
Skip to footer

A beginner’s guide to AI driven pharmacovigilance platform

Dr. Alejandra Guerchicoff

Industry Leader – TCS ADD Safety, TCS

Michael Murphy

Executive Director, Head of Pharmacovigilance Operations, Amgen

You have these already downloaded

We have sent you a copy of the report to your email again.

New-age AI technologies and cognitive automation solutions can make the pharmacovigilance (PV) process faster, agile, consistent, accurate, compliant and more efficient. Even though there is no viable “one-size-fits-all” approach to adopting an AI-based PV solution, there is a consensus that technology is an imperative for transforming the PV approach for Life Sciences organizations. We believe the information gathered from our experience clearly presents benefits of AI on operational safety case processing and transformative impact on PV. This paper will guide you to:

  • Leverage an AI-driven platform to increase productivity, improve product safety analysis, drive business growth, support in budgetary responsibility and bring innovation
  • Realize a digital organization with performance excellence capabilities through enterprise agility and digital AI case processing
Read More

About the authors

Dr. Alejandra Guerchicoff
Dr. Alejandra Guerchicoff is a PhD in molecular genetics with a post-doctoral training in molecular cardiology. She is working as an Industry Advisor for TCS ADD platform with the Life Sciences unit at Tata Consultancy Services (TCS). Dr. Guerchicoff possesses a rich experience of more than 20 years in the domain of clinical research and post-marketing pharmacovigilance, for medical devices, drugs, combination products, gene and cell therapy, and software as medical device products.
Read more about authorRead more about author Read more about author
Michael Murphy
Michael D. Murphy leads the PV Operations team within Global Patient Safety at Amgen, a position he has held since April 2019. Responsibilities include overseeing and managing teams accountable for adverse event case processing and medical review, periodic reporting, safety reporting obligations for clinical, commercial/marketing programs, and oversight of the safety technologies.
Read more about authorRead more about author Read more about author

Related reading

Next-gen clinical trials on a digital platform

Customer Testimonial | 27 Jan 2023

Adopting a Design Thinking Approach for Risk-Based Monitoring

White Paper | 23 Dec 2022

The new age digital contract research organizations

White Paper | 23 Dec 2022

Bayer overhauls its trial planning process

White Paper | 23 Dec 2022

Transformation starts here

Learn how we can help you bring drugs to the market faster.

Talk to our experts

Find out more